117 related articles for article (PubMed ID: 12747280)
1. Impaired expression of erythrocyte glycosyl-phosphatidylinositol-anchored membrane CD59 in patients with psoriatic arthritis. Relation to terminal complement pathway activation.
Triolo G; Accardo-Palumbo A; Sallì L; Ciccia F; Ferrante A; Tedesco L; Sallì S; Giardina E; Pappalardo A; Licata G
Clin Exp Rheumatol; 2003; 21(2):225-8. PubMed ID: 12747280
[TBL] [Abstract][Full Text] [Related]
2. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.
Harris CL; Morgan BP
Immunology; 1995 Oct; 86(2):311-8. PubMed ID: 7490134
[TBL] [Abstract][Full Text] [Related]
4. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
Lehto T; Meri S
J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
[TBL] [Abstract][Full Text] [Related]
5. CD59 efficiently protects human NT2-N neurons against complement-mediated damage.
Pedersen ED; Aass HC; Rootwelt T; Fung M; Lambris JD; Mollnes TE
Scand J Immunol; 2007; 66(2-3):345-51. PubMed ID: 17635812
[TBL] [Abstract][Full Text] [Related]
6. [Glycosylphosphatidylinositol-anchored proteins with complement-regulatory activity on erythrocytes].
Kawaguchi T; Nakakuma H
Nihon Rinsho; 1996 Sep; 54(9):2370-5. PubMed ID: 8890564
[TBL] [Abstract][Full Text] [Related]
7. Levels of SC5b--9 complement complex in plasma and synovial fluid of patients with rheumatic disease.
Rus V; Malide D; Boloşiu HD; Parasca I; Duţu AL
Med Interne; 1990; 28(4):305-10. PubMed ID: 2100875
[TBL] [Abstract][Full Text] [Related]
8. Generation of terminal complement complexes in psoriatic lesional skin.
Takematsu H; Tagami H
Dermatology; 1992; 185(4):246-50. PubMed ID: 1477417
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies.
Kemp PA; Spragg JH; Brown JC; Morgan BP; Gunn CA; Taylor PW
J Clin Lab Immunol; 1992; 37(4):147-62. PubMed ID: 1285067
[TBL] [Abstract][Full Text] [Related]
10. CD59: a molecule involved in antigen presentation as well as downregulation of membrane attack complex.
Venneker GT; Asghar SS
Exp Clin Immunogenet; 1992; 9(1):33-47. PubMed ID: 1379443
[TBL] [Abstract][Full Text] [Related]
11. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
[TBL] [Abstract][Full Text] [Related]
12. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
13. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction.
Väkevä A; Laurila P; Meri S
Lab Invest; 1992 Nov; 67(5):608-16. PubMed ID: 1279272
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal mesothelial cells produce complement factors and express CD59 that inhibits C5b-9-mediated cell lysis.
Barbano G; Cappa F; Prigione I; Tedesco F; Pausa M; Gugliemino R; Pistoia V; Gusmano R; Perfumo F
Adv Perit Dial; 1999; 15():253-7. PubMed ID: 10682113
[TBL] [Abstract][Full Text] [Related]
16. Complement-regulatory protein expression and activation of complement cascade on erythrocytes from patients with rheumatoid arthritis (RA).
Arora M; Kumar A; Das SN; Srivastava LM
Clin Exp Immunol; 1998 Jan; 111(1):102-6. PubMed ID: 9472668
[TBL] [Abstract][Full Text] [Related]
17. Host cell factor CD59 restricts complement lysis of Plasmodium falciparum-infected erythrocytes.
Wiesner J; Jomaa H; Wilhelm M; Tony HP; Kremsner PG; Horrocks P; Lanzer M
Eur J Immunol; 1997 Oct; 27(10):2708-13. PubMed ID: 9368630
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.
Saifuddin M; Hedayati T; Atkinson JP; Holguin MH; Parker CJ; Spear GT
J Gen Virol; 1997 Aug; 78 ( Pt 8)():1907-11. PubMed ID: 9266986
[TBL] [Abstract][Full Text] [Related]
19. Protection of porcine aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59.
Kennedy SP; Rollins SA; Burton WV; Sims PJ; Bothwell AL; Squinto SP; Zavoico GB
Transplantation; 1994 May; 57(10):1494-501. PubMed ID: 7515200
[TBL] [Abstract][Full Text] [Related]
20. Glucose-induced loss of glycosyl-phosphatidylinositol-anchored membrane regulators of complement activation (CD59, CD55) by in vitro cultured human umbilical vein endothelial cells.
Accardo-Palumbo A; Triolo G; Colonna-Romano G; Potestio M; Carbone M; Ferrante A; Giardina E; Caimi G; Triolo G
Diabetologia; 2000 Aug; 43(8):1039-47. PubMed ID: 10990082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
